sarepta elevidys - Search News

Order byBest matchMost fresh

Sarepta reports 2nd case of liver failure death

Sarepta downgraded as company suspends guidance after latest Elevidys death

Wall Street analysts were quick to downgrade Sarepta Therapeutics (NASDAQ:SRPT) on Monday as the company suspended its revenue guidance for 2025 following a second fatality linked to Elevidys, its gene therapy for Duchenne muscular dystrophy.

· 1d

Sarepta Shares Dive on Second Fatal Liver Failure Tied to Elevidys

· 1d · on MSN

Sarepta reports second case of liver failure death after its gene therapy treatment

Sarepta shares crash

Digest more

· 21h · on MSN

Sarepta Stock Plunges After Death of Second Patient Receiving Its Gene Therapy

Sarepta Therapeutics stock plummeted Monday after the company said a second patient receiving its gene therapy died from liver failure, raising serious questions on the drug’s outlook.Shares fell 40% to $21.

BioSpace · 22h

UPDATE: Second Patient Dies After Receiving Sarepta’s DMD Gene Therapy Elevidys

· 22h · on MSN

Sarepta Therapeutics Stock Plunges as Second Patient Dies Taking Its Drug

· 15h

Second patient death reported with gene therapy for muscular dystrophy

Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.

· 1d

Sarepta crashes after second death linked to Roche-partnered Elevidys

· 1d

Sarepta Therapeutics: Rebuilding The Thesis After Hitting Rock Bottom

STAT17h

After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry

Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other parents still push for the therapy.

Business Wire1d

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause.